Xanthus Company Description
Knowing your phenotype could help make your cancer treatment phenomenal. Xanthus Pharmaceuticals is creating customized cancer treatments that take into account not just a patient's height and weight but also his or her lifestyle, including diet, metabolism, and organ function prior to beginning treatment. These factors can determine how a cancer patient responds to his or her treatment. Xanthus Pharmaceuticals has three drug candidates in its pipeline: Xanafide for prostate cancer and acute myeloid leukemia, and Clomet and Symadex for solid tumors.
View the Comprehensive Company Description for Xanthus
The Company Description provides a historical perspective of Xanthus's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Xanthus's evolution in the marketplace.
